Vor Biopharma Inc.
VOR
$33.80
-$1.89-5.28%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 21.65M | 26.46M | 27.88M | 29.14M | 30.15M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 336.67M | 122.15M | 121.19M | 118.00M | 124.80M |
Operating Income | -336.67M | -122.15M | -121.19M | -118.00M | -124.80M |
Income Before Tax | -1.66B | -118.60M | -116.91M | -112.46M | -118.09M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -1.66K | -118.60 | -116.91 | -112.46 | -118.09 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -1.66B | -118.60M | -116.91M | -112.46M | -118.09M |
EBIT | -336.67M | -122.15M | -121.19M | -118.00M | -124.80M |
EBITDA | -332.09M | -118.74M | -117.66M | -114.44M | -121.20M |
EPS Basic | -273.27 | -30.18 | -34.03 | -33.00 | -34.77 |
Normalized Basic EPS | -167.73 | -18.86 | -21.27 | -20.63 | -21.73 |
EPS Diluted | -273.27 | -30.18 | -34.03 | -33.00 | -34.77 |
Normalized Diluted EPS | -167.73 | -18.86 | -21.27 | -20.63 | -21.73 |
Average Basic Shares Outstanding | 19.43M | 16.58M | 13.74M | 13.63M | 13.59M |
Average Diluted Shares Outstanding | 19.43M | 16.58M | 13.74M | 13.63M | 13.59M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |